HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCBB: BPTH) (“Bio-Path”), a biotechnology company with drug development operations in Houston, announced today that it has signed an equity purchase agreement for up to $7 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Bio-Path is developing a neutral lipid-based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules), a delivery technology that forms tiny vehicles to safely deliver these drugs to their intended target cancer cells. The U.S. Food and Drug Administration (FDA) has recently allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.
